Zurich Extends Cannabis Trial as Legal Sales Top 750kg

Zurich is not just continuing its experiment with legal cannabis; it is aggressively expanding it. In a decisive move that signals strong confidence in the "Züri-Can" project, the City Council has formally applied to extend the pilot program until 2028. The numbers driving this decision are undeniable. Consumers have already purchased a staggering 750 kilograms of regulated cannabis, proving that the demand for a legal, safe alternative is not just present—it is overwhelming.

Originally slated to conclude in 2026, the two-year extension marks a pivotal shift in Swiss drug policy implementation. With over 2,300 participants currently enrolled, the city is moving beyond tentative testing into a robust operational phase. This is no longer a fringe experiment; it is a functioning parallel market that has successfully facilitated 88,000 individual sales transactions. By pushing the timeline to 2028, Zurich is effectively declaring that the regulated model is not only viable but essential for gathering long-term data on consumption habits. The city is seizing the opportunity to solidify its position as a pioneer in progressive drug policy, refusing to let the momentum of this initial success fade.

The "Züri-Can" project has delivered a massive financial blow to illegal dealers, stripping an estimated CHF 7.5 million directly from the black market. This is not a theoretical projection; it is hard cash that has been siphoned away from criminal networks and channeled into a controlled, transparent system. Every franc of that CHF 7.5 million represents a transaction that took place without the dangers, impurities, and violence often associated with the illicit trade.

While critics often debate the morality of legalization, the economic reality in Zurich speaks for itself. The city has successfully created a safe harbor for consumers, evidenced by the 88,000 legal sales recorded to date. This massive transfer of wealth from the shadows to the light validates the core economic hypothesis of the pilot: if you offer a safe, quality-controlled product, consumers will abandon the street corner for the dispensary. The city is effectively dismantling the local illicit trade brick by brick, proving that regulation is a far more potent weapon against the black market than prohibition ever was.

The face of Zurich's cannabis consumer is changing, and the city is actively engineering this shift. Acknowledging that the current participant base does not fully reflect the general population, officials are launching a targeted effort to attract underrepresented groups: specifically women and occasional users. This is a critical evolution for the study's scientific validity. To facilitate this, the federal government authorized a significant cap increase in July 2025, raising the participant limit from 2,100 to 3,000.

This expansion is about more than just numbers; it is about normalization. By actively courting casual smokers and women, the "Züri-Can" project is moving away from the stereotype of the heavy, male-dominated stoner culture. The goal is to capture a realistic cross-section of society to understand how regulated access impacts different demographics. Bringing these "invisible" users into the fold allows researchers to gather data on moderate consumption patterns that have previously been ignored. Zurich is not just selling cannabis; it is building a comprehensive social map of its usage across all strata of the city.

Zurich is putting a CHF 800,000 price tag on the future of public health. This investment, required to fund the extension until 2028, underscores the city's commitment to a science-led approach. City Councillor Andreas Hauri has been explicit about the mission: the project centers squarely on health and protecting users from the volatile risks of the unregulated market. This is not a commercial endeavor; it is a public safety operation supervised by the rigorous standards of the Psychiatric University Clinic Zurich.

In a landscape where synthetic cannabinoids and contaminants plague street drugs, this state-sponsored trial offers a lifeline of safety. The CHF 800,000 allocation ensures that the Psychiatric University Clinic can continue its vital monitoring work, analyzing the long-term mental and physical effects of regulated consumption. By prioritizing data over dogma, Zurich is constructing a blueprint for the rest of Switzerland—and potentially Europe. The city is betting that the cost of the trial pales in comparison to the long-term savings in public health and law enforcement costs.